Jason Niu, MD, PhD, discusses treatment updates in RET fusion–positive and KRAS-mutant non–small cell lung cancer.
Jiaxin (Jason) Niu, MD, PhD
Advertisement
Articles by Jiaxin (Jason) Niu, MD, PhD
Jason Niu, MD, PhD, discusses considerations for selecting between selpercatinib and pralsetinib in RET fusion–positive non–small cell lung cancer.
Jiaxin (Jason) Niu, MD, PhD, discusses combining immunotherapy with VEGF Inhibitors in extensive-stage small cell lung cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer
3
Bispecific-Based Approaches Highlight Key Multiple Myeloma Data Set to Emerge at EHA 2026
4
HERTHENA-Breast04 Is Set to Delineate the Role of HER3-Targeted Therapy in Advanced HR+ Breast Cancer
5